FindTrial
Sign In

Valsartan 160 mg and hydrochlorothiazide 25 mg in subject suffering from arterial hypertension stage 1 or high normal with organ damage - ND

Valsartan 160 mg and hydrochlorothiazide 25 mg in subject suffering from arterial hypertension stage 1 or high normal with organ damage - ND

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2008-000804-10-IT
Enrollment
Unknown
Registered
2009-05-25
Start date
2008-03-31
Completion date
Unknown
Last updated
2012-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial Hypertension with organ damage

Interventions

Trade Name: CORIXIL Pharmaceutical Form: Tablet INN or Proposed INN: VALSARTAN CAS Number: 137862-53-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 160- INN or P

Sponsors

UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: -age between 18 and 65 -male -High-normal arterial blood pressure(PA 130-139/85-89 mmHg) -Essential hypertension of grade1 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Endocrine -Unable to practice stress-test by cicloergometer -Mellitus diabet -Anemia (Hb<12,5 g/dl) -Cardiac valvular e/o arhythmic disease

Design outcomes

Primary

MeasureTime frame
Primary end point(s): A better pressure control with significative improvement of organ damage;Main Objective: Percentual of patients that normalize arterial blood pressure;Secondary Objective: Reduction of left ventricular mass; reduction of arterial stiffness—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026